Novo Nordisk’s Liraglutide Adds Thyroid Cancer Risk To The Diabetes Safety Gauntlet

In addition to weighing prior data against new cardiovascular outcomes standards, FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will assess April 2 whether a cancer risk in rodents translates to humans.